Back to search

Democritus University of Thrace (DUTH)

Πλαστικότητα των ουδετεροφίλων και ρύθμιση της φλεγμονώδους απόκρισης

Abstract

dc:description

Introduction: Neutrophils constitute integral components of innate immunity and major contributors to thromboinflammation and tissue damage. Neutrophil plasticity, i.e., the ability of the mature cells to acquire phenotypic heterogeneity and functional flexibility when exposed to different stimuli of the inflammatory microenvironment, has been recently recognized as a key aspect of their biology. The generation and release of neutrophil extracellular traps (NETs), chromatin structures decorated with active proteins, comprises a predominant expression of neutrophil plasticity. Numerous studies demonstrate the release of NETs (NETosis) as an important defense mechanism. However, recent data link dysregulation of the innate immune response, leading to marked NETosis, to the induction of inflammation and thrombosis. Severe SARS-CoV-2 infection (COVID-19) stands as a recently recognized example of a disease characterized by dysregulated immune response and increased release of NETs. It is associated with high rates of intubation, in-hospital mortality, and secondary complications, such as micro- and macro-thrombosis and pulmonary fibrosis, often reflecting the robust underlying processes of thromboinflammation and immunofibrosis. Krüppel-like factor 2 (KLF2) is a transcription factor linked with neutrophil-associated fibrosis and thromboinflammation. However, its role in COVID-19 remains elusive. Objectives: Considering the heterogeneity and complexity of the mechanisms that characterize the dysregulation of the immune response in severe COVID-19, combined rescue immunomodulatory treatment (COMBI) was applied for the first time on top of standard-of-care treatment (SOC), aiming to reduce the need for mechanical ventilation and mortality, in non-intubated patients with COVID-19-related severe respiratory failure (PaO2/FiO2 <100 mmHg). In the experimental part of this PhD thesis, the crosstalk between the neutrophil/NETs axis and human lung fibroblasts (LFs) was investigated, as well as the effect of plasma on LFs’ thrombotic and fibrotic potential, in the context of severe COVID-19. The possible correlation between the fibrotic activity of LFs and KLF2 expression in the COVID-19 environment was also explored. Concurrently, a comparative study of the clinical data from patients subjected to different immunomodulatory interventions was conducted, correlating the findings with the research results. The broader purpose of this research was the identification of potential future prognostic and therapeutic targets in immunofibrotic diseases with a similar pathogenetic background. Materials and methods: In the clinical part of the study, 4 groups of patients with severe respiratory failure (SRF), subjected to different treatment interventions, were analyzed and compared. Specifically, the effect of COMBI treatment, comprising inhaled DNase I, baricitinib, and tocilizumab, to dismantle NETs and inhibit JAK1/2 and IL-6 signaling, respectively, was studied. COMBI treatment was compared with SOC or immunomodulatory monotherapies against IL-1 (anakinra) or IL-6 (tocilizumab). In the translational-research component of the study, human lung fibroblasts (LFs) were isolated from patients undergoing diagnostic lung biopsy. In vitro stimulations of LFs were conducted using either plasma, obtained from treatment-naïve patients with severe COVID-19, or NET structures, isolated after in vitro incubation of healthy neutrophils with patients’ plasma (COV NETs). RT-qPCR, in-cell ELISA (Cytoblot), immunofluorescence microscopy, collagen measurement and functional wound healing assays were performed to evaluate the effect of COVID-19 environment (plasma or NETs) on LFs. In vitro inhibition studies were conducted, using the agents of COMBI protocol (DNase I, baricitinib, tocilizumab), to investigate the role of NETs, JAK1/2 and IL-6 signaling, respectively. Results: At the clinical level, COMBI treatment was associated with lower in-hospital mortality, reduced intubation rate, shorter duration of hospitalization, and prolonged overall survival, compared to other therapeutic interventions. At the experimental level, in vitro stimulation of LFs with COVID-19 environment induced the tissue factor (TF)/thrombin pathway, while pre-incubation with COMBI agents significantly inhibited this effect. Furthermore, upon incubation with COVID-19 plasma or COV NETs, LFs acquired a pre-fibrotic phenotype, characterized by increased expression of CCN2 (Cellular Communication Network Factor 2), a growth factor consistently associated with fibrotic remodeling, and increased collagen production. This effect was correlated with the down-regulation of KLF2 in LFs. However, pre-incubation of LFs with the agents of the COMBI protocol restored the reduced expression of KLF2, while mitigating their fibrotic activity. Plasma isolated from COMBI-treated patients at day 7 was characterized by a significantly reduced ability to induce the fibrotic potential of LFs (lower CCN2 expression and simultaneous restoration of the reduced expression of KLF2), compared to the plasma of SOC-treated patients. Conclusions: Collectively, COMBI rescue treatment was associated with improved clinical outcomes, compared to SOC therapy or immunomodulatory monotherapies. Severe COVID-19 environment induces the thrombotic and fibrotic potential of LFs through different pathways, including the neutrophil/NETs axis, JAK1/2 signaling, and IL-6. The dismantling of NETs by DNase I, and the subsequent inactivation of the mediators they contain, highlight, on one hand, the central role of NETosis, a process of neutrophil plasticity expression, in the thromboinflammatory and immunofibrotic process in COVID-19 and, on the other hand, the structural integrity of NETs as a prerequisite for maintaining their functionality. The in vitro results emerging from inhibition of the TF/thrombin axis and the fibrotic pathway in LFs are consistent with the above clinical observations, providing a plausible mechanistic explanation. Furthermore, the negative correlation between KLF2 expression and the fibrotic activity of LFs, suggests KLF2 as a significant regulator of the fibrotic process in severe COVID-19. Overall, the findings of this study hold potential for future applications in other acute or chronic inflammatory immunofibrotic conditions pathogenetically related to COVID-19.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Antoniadou, Christina
  • Αντωνιάδου, Χριστίνα

Subjects

dc:subject × 25

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/55499

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Antoniadou, Christina; Αντωνιάδου, Χριστίνα. Πλαστικότητα των ουδετεροφίλων και ρύθμιση της φλεγμονώδους απόκρισης. Democritus University of Thrace (DUTH), 2023. http://hdl.handle.net/10442/hedi/55499